These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 17698326)

  • 1. Pseudomonas aeruginosa bloodstream infections: how should we treat them?
    van Delden C
    Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S71-5. PubMed ID: 17698326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
    Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
    Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
    Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
    J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():17-32. PubMed ID: 15953020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.
    Schechner V; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Finkelstein R; Lachish T; Wiener-Well Y; Alon D; Chowers M; Bardenstein R; Zimhony O; Paz A; Potasman I; Giladi M; Schwaber MJ; Klarfeld-Lidji S; Hochman M; Marchaim D; Carmeli Y
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):38-45. PubMed ID: 21763093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.
    Kang CI; Kim SH; Kim HB; Park SW; Choe YJ; Oh MD; Kim EC; Choe KW
    Clin Infect Dis; 2003 Sep; 37(6):745-51. PubMed ID: 12955633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
    Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
    J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the treatment of Pseudomonas aeruginosa pneumonia.
    El Solh AA; Alhajhusain A
    J Antimicrob Chemother; 2009 Aug; 64(2):229-38. PubMed ID: 19520717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum.
    Traugott KA; Echevarria K; Maxwell P; Green K; Lewis JS
    Pharmacotherapy; 2011 Jun; 31(6):598-608. PubMed ID: 21923444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort.
    Peña C; Suarez C; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Oliver A; Martínez-Martínez L;
    Clin Infect Dis; 2013 Jul; 57(2):208-16. PubMed ID: 23580739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
    Tumbarello M; Repetto E; Trecarichi EM; Bernardini C; De Pascale G; Parisini A; Rossi M; Molinari MP; Spanu T; Viscoli C; Cauda R; Bassetti M
    Epidemiol Infect; 2011 Nov; 139(11):1740-9. PubMed ID: 21226988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies.
    Hu Y; Li L; Li W; Xu H; He P; Yan X; Dai H
    Int J Antimicrob Agents; 2013 Dec; 42(6):492-6. PubMed ID: 24139926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia.
    Tam VH; Chang KT; Schilling AN; LaRocco MT; Genty LO; Garey KW
    Diagn Microbiol Infect Dis; 2009 Mar; 63(3):279-85. PubMed ID: 19135330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
    Chamot E; Boffi El Amari E; Rohner P; Van Delden C
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2756-64. PubMed ID: 12936970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
    Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
    Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient.
    Sun HY; Shields RK; Cacciarelli TV; Muder RR; Singh N
    Transpl Infect Dis; 2010 Dec; 12(6):555-60. PubMed ID: 20626709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.
    Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
    J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
    Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
    Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.